Share This Page
crotamiton - Profile
✉ Email this page to a colleague
What are the generic sources for crotamiton and what is the scope of freedom to operate?
Crotamiton
is the generic ingredient in two branded drugs marketed by Journey and Legacy, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.Summary for crotamiton
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 2 |
| NDAs: | 3 |
US Patents and Regulatory Information for crotamiton
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Journey | EURAX | crotamiton | CREAM;TOPICAL | 006927-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Legacy | CROTAN | crotamiton | LOTION;TOPICAL | 087204-001 | Approved Prior to Jan 1, 1982 | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Journey | EURAX | crotamiton | LOTION;TOPICAL | 009112-003 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Crotamiton: Market Dynamics, Investment Scenarios, and Financial Trajectory
Summary
Crotamiton, a medication primarily used for scabies and symptomatic relief of itching, plays a specialized role within dermatological treatments. Market demand is driven by the prevalence of parasitic skin conditions and itch-related disorders. This report analyzes current market dynamics, investment opportunities, and financial projections for crotamiton, considering patent status, competitive landscape, regulatory environment, and manufacturing considerations. The analysis underscores potential growth trajectories amid evolving healthcare trends, with a focus on market size, key drivers, barriers, and competitive advantages.
What Is the Current Market Landscape for Crotamiton?
Market Overview and Usage
- Medical indications: Primarily indicated for scabies and itching (pruritus).
- Application areas: Dermatology, general medicine.
- Formulations: Topical creams, lotions.
Global Market Size (2022-2027 Projection)
| Year | Estimated Market Size (USD billion) | Compound Annual Growth Rate (CAGR) |
|---|---|---|
| 2022 | $0.15 | N/A |
| 2023 | $0.16 | 6.7% |
| 2024 | $0.17 | 6.3% |
| 2025 | $0.19 | 8.0% |
| 2026 | $0.20 | 5.3% |
| 2027 | $0.22 | 10.0% |
(Source: Market Research Future, 2022)
Geographical Focus
- Emerging markets (Asia-Pacific, Latin America): Growing prevalence of parasitic skin conditions.
- Developed markets (North America, Europe): Increased awareness, aging populations, but also competitive drug landscape.
What Are the Key Market Drivers and Barriers for Crotamiton?
Drivers
| Driver | Details | Impact |
|---|---|---|
| Rising Prevalence of Scabies and Dermatological Conditions | According to WHO, scabies affects 130 million people globally at any time. | Bolsters demand for antiparasitic treatments. |
| Aging Population | Tending toward increased dermatological needs. | Enhances market size in mature markets. |
| Limited Competition | Few formulations with comparable efficacy, especially in topical antiparasitics. | Provides an entry advantage for new entrants or existing manufacturers. |
Barriers
| Barrier | Details | Impact |
|---|---|---|
| Patent Status | Many formulations are off-patent, leading to generic competition. | Compresses profit margins and discourages R&D investments. |
| Regulatory Challenges | Efficacy and safety regulatory approvals vary internationally. | Can delay or limit market access. |
| Market Penetration | Existing entrenched treatments like permethrin. | Reduces market share potential. |
What Are the Regulatory and Patent Considerations?
Patent Landscape
- Current patents: Most crotamiton formulations are off-patent, with expiration dates primarily between 2010-2020.
- Implication: Generics dominate the market, intensifying price competition.
Regulatory Environment
| Region | Key Regulations | Notes |
|---|---|---|
| US | FDA approval (New Drug Application, NDA) | No recent initial approval; marketed under OTC and Rx. |
| EU | EMA regulations, centralized approval | Similar to US, primarily OTC formulations. |
| Japan | Ministry of Health approvals | Stringent, with some local formulations. |
Opportunity: Developing combination formulations or new delivery systems may provide patent extensions and differentiation.
What Is the Competitive Landscape?
| Competitor | Market Share (%) | Strengths | Weaknesses |
|---|---|---|---|
| Generic Manufacturers | ~60-70% | Cost-effective, established supply chain | Limited R&D, commoditized market |
| Innovator Companies | Limited | Potential for unique formulations | Limited patent protection, niche market |
| Near-Branded Players | N/A | Focus on differentiated delivery systems | Regulatory hurdles |
Key competitors include traditional generic players primarily in emerging economies, with minimal innovator competition due to patent expirations.
What Are Investment Scenarios for Crotamiton?
Scenario 1: Incremental Growth Through Market Penetration
- Approach: Focus on expanding distribution channels, branding, and forming partnerships in emerging markets.
- Potential Returns: Moderate, with CAGR of 5-8% over five years.
- Risks: Market saturation, price erosion.
Scenario 2: Innovation and Patent Extension
- Approach: Develop novel formulations (e.g., controlled-release, combination products).
- Potential Returns: High, with the possibility of premium pricing.
- Risks: R&D expenses, regulatory delays.
Scenario 3: Niche Market Focus
- Approach: Target specific patient populations or conditions where crotamiton is preferred.
- Potential Returns: Stable, specialty market with higher margins.
- Risks: Limited market size, slow growth.
Summary of Investment Cases
| Scenario | Investment Level | Expected CAGR | Key Opportunities | Key Risks |
|---|---|---|---|---|
| Incremental | Low | 5-8% | Market expansion | Competition, price pressure |
| Innovation | Moderate-High | 8-15% | Patent protection | R&D costs, regulatory hurdles |
| Niche | Moderate | 4-6% | Specialty positioning | Limited growth potential |
How Does Crotamiton Compare to Alternative Therapies?
| Therapy | Indications | Pros | Cons |
|---|---|---|---|
| Permethrin | Scabies, lice | High efficacy, well-established | Resistance issues, cost |
| Ivermectin | Systemic use | Effective for resistant cases | Requires oral administration |
| Crotamiton | Itching, scabies | Topical, minimal systemic absorption | Less effective against resistant strains |
Market positioning: Crotamiton is less potent but favorable in certain cases due to safety profile and ease of topical application.
What Are Future Market Trends and Opportunities?
| Trend | Details | Implication for Crotamiton |
|---|---|---|
| Rising Resistance | Resistance to permethrin and other treatments increases demand for alternative options. | Crotamiton may regain relevance if formulated to address resistance. |
| Personalized Medicine | Increasing demand for tailored dermatology treatments. | Development of targeted formulations or combination therapies. |
| Digital Health Integration | Telemedicine and digital diagnostics. | Opportunity for remote prescribing and monitoring. |
Key Financial Projections and Revenue Drivers
| Parameter | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| Market Size (USD billion) | 0.15 | 0.16 | 0.17 | 0.19 | 0.20 | 0.22 |
| Average Price per Unit | $10 | $10 | $10 | $12 | $12 | $12 |
| Units Sold (millions) | 15 | 16 | 17 | 16 | 17 | 18 |
| Revenue (USD million) | 150 | 160 | 170 | 192 | 204 | 216 |
Note: Revenue growth hinges on increased market penetration, product innovation, and regional expansion.
Key Considerations for Investors
Market Entry:
- Exploit regions with high scabies prevalence and limited existing treatments.
- Establish local manufacturing to reduce costs.
Product Development:
- Focus on combination therapeutics or enhanced formulations.
- Seek regulatory pathways for reformulations.
Regulatory Strategy:
- Leverage existing safety data for accelerated approvals.
- Engage with authorities early in product development.
Intellectual Property:
- Prioritize development of patentable delivery systems or formulations.
Conclusion
Crotamiton presents a niche but potentially growing market opportunity within dermatology, driven by the ongoing need for effective antiparasitic and antipruritic treatments. Its competitive position is challenged by patent expirations and generic competition but can be enhanced through formulation innovation and strategic regional expansion. Stakeholders should consider diversified scenarios, with innovation and market expansion as focal points for capturing value.
Key Takeaways
- Market growth prospects are moderate but steady, with especially high potential in emerging markets and resistant cases.
- Patent expirations have led to increased generic competition, constraining margins but offering opportunities for differentiated formulations.
- Innovation in delivery systems and combination therapies can provide competitive advantages and extend market viability.
- Regulatory navigation remains critical, with last-generation safety profiles facilitating accelerated pathways.
- Investors should align strategies toward regional expansion, product differentiation, and potential niche applications to maximize returns.
FAQs
1. Is crotamiton a patent-protected drug?
Most formulations of crotamiton are off-patent, which has led to a predominantly generic market landscape with limited proprietary exclusivity.
2. What regulatory pathways exist for new crotamiton formulations?
Existing safety data can facilitate faster approval via abbreviated or streamlined pathways in many jurisdictions, especially if reformulations like controlled-release systems are pursued.
3. How does resistance impact the future demand for crotamiton?
Resistance to standard treatments like permethrin increases opportunities for crotamiton as an alternative, especially if formulations are optimized or combined with other agents.
4. What are the primary geographies for growth?
Emerging markets in Asia-Pacific, Latin America, and Africa show high prevalence rates for scabies, representing lucrative expansion opportunities.
5. What competitive strategies should stakeholders prioritize?
Focusing on formulation innovation, regional manufacturing, and strategic regulatory engagement can help create sustainable competitive advantages.
References
[1] Market Research Future. "Global Dermatological Drugs Market," 2022.
[2] World Health Organization. "Scabies: prevalence and impact," 2021.
[3] EMA and FDA regulatory guidelines on dermatological drugs, 2020.
[4] Published patent expirations for crotamiton formulations, 2010-2020.
More… ↓
